Kornimate/medical-research-clean huggingface dataset:
role of turmeric on oxidative modulation in esrd patients

Conditions: End Stage Renal Failure

Summary: despite advances in prevention of cardiovascular diseases, the incidence of accelerated atherosclerosis in hemodialysis (hd) patients has still remained high. oxidative stress is considered as a major player in uremia associated morbidity and mortality in hd patients. the aim of this study was to evaluate the effects of turmeric on oxidative stress markers in hd patients.

end-stage renal disease (esrd) is a state of oxidative stress, due to uremic oxidant mediator's accumulation, the activation of phagocytic oxidative metabolism by the dialysis membrane, intravenous iron therapy and the antioxidant depletion caused by hemodialysis (hd). some trials showed a significant benefit from antioxidant therapy on cardiovascular outcome in hd patients. extensive research focused on direct exogenous antioxidants including vitamin c, and vitamin e, in the treatment of cardiovascular disease. some clinical trials showed no more beneficial effect of exogenous antioxidant supplementation in cardiovascular disease (cvd) and recommended the necessity for a new approach to regulating cellular redox status. turmeric (curcuma longa linn) is an herb used as a dietary spice and in traditional medicine for centuries. curcumin, the most active and non-toxic component of turmeric, is a polyphenol, which has been extensively studied for its therapeutic benefits, such as antioxidant. besides, turmeric has also been effective in attenuation of proteinurea in diabetic nephropathy and lupus nephritis patients. curcumin restored the activities of mitochondrial enzymes complexes and thereby attenuated the release of reactive oxygen species. turmeric appears to be non-toxic to humans even at high doses. however, there is a paucity of information on the effect of turmeric in hd population. we have, therefore, followed up this study to determine the beneficial effect of turmeric on oxidative stress in hd patients.

Eligibility criteria:
inclusion criteria: * having the age of 18 years and more, * receiving 4-hour hd treatments 3 times per week at least for three months, * administering no other antioxidant medications exclusion criteria:

Keywords: chronic renal failure hemodialysis oxidative stress turmeric
effect of metformin and probiotics in reproductive-aged patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this clinical trial is to evaluate the safety and effectiveness on the clinical and biological parameters of reproductive-aged pcos women after a 12-week metformin and/or probiotics administration.

probiotics are live bacteria that offer a health benefit to the host when administered in adequate amounts. probiotic supplementation is safe for use and has demonstrated beneficial effects for metabolic diseases such as obesity and diabetes. in this study, about 90 reproductive-aged women with pcos will be enrolled. participants will be randomly assigned into one of the following three groups: metformin tablets (0.5g tid po), promets probiotics powder (4g qn po), metformin tablets (0.5g tid po) and promets probiotics powder (4g qn po), for 12 weeks. blood and stool samples will be collected before and after treatment. fasting glucose levels, fasting insulin levels, sex hormone levels, serum lipid profiles, inflammation markers, other metabolic related parameters and change of gut microbiota and immune cells will be evaluated.

Eligibility criteria:
inclusion criteria: 1. premenopausal between 18-40 years of age. 2. diagnosed pcos defined as 2003 rotterdam diagnostic criteria. exclusion criteria: 1. during the pregnancy and lactation period. 2. significant impaired liver function, impaired renal function, mental disease, severe infection, severe anemia, severe heart disease and neutropenia disease. 3. use of antibiotics within 3 months. 4. symptoms of any infection at screening. 5. immunodeficient or use of immunosuppressive drugs. 6. use of products containing prebiotics or probiotics within the last 3 months. 7. previous history of gastrointestinal surgery or disease (such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease or other gastrointestinal disorder). 8. medical conditions or diseases that may affect subject safety or confound study results in the opinion of the investigator
effect of wheat dextrin on calcium and magnesium absorption

Conditions: Colonic Inertia

Summary: to compare calcium and magnesium absorption within subjects with and without chronic consumption of wheat dextrin.


Eligibility criteria:
inclusion criteria: - subjects will be generally healthy caucasian females aged 19 and older with no known abnormalities of gastrointestinal function, and taking no medications that might alter absorptive performance. bmi will be between 19 and 31 kg/m2 -

Keywords: fiber calcium magnesium
effect of dairy consumption on glycemic control, body weight and cardiovascular risk factors

Conditions: Diabetes Mellitus, Type 2; Obesity

Summary: the aim of this study is to determine the relationship between the percentage of calories from dairy intake and long-term glycemic control and weight maintenance in patients with type 2 diabetes who participate in an intensive lifestyle intervention program. the investigators hypothesize that overweight and obese patients with type 2 diabetes who consume higher percentage of calories from dairy products during intensive lifestyle intervention programs have better glycemic control and maintenance of weight loss as compared to those who consume lower percentage of calories from dairy products.

this is a prospective, observational clinical study where the daily intake of dairy products will be recorded and analyzed in 50 overweight/obese subjects with type 2 diabetes enrolled in the weight achievement and intensive treatment (why wait) program. the weight achievement and intensive treatment (why wait) program is a 12-week multidisciplinary program developed by joslin diabetes center for intensive diabetes weight management in clinical practice. it includes the following components that are provided in a group setting: (1) intensive medical treatment provided by an endocrinologist and a registered nurse; (2) a structured dietary plan provided by a registered dietitian; (3) an individualized exercise training program provided by an exercise physiologist; (4) cognitive behavioral modification provided by a behavioral therapist. participants will be enrolled in this study for a period of 24 weeks. they will attend the weight achievement and intensive treatment (why wait) program during the first 12 weeks of the study and will be followed for another 12 weeks after the program (the maintenance phase). during the intervention phase, participants will receive group education on a weekly basis for 12 consecutive weeks. during maintenance phase, participants will receive a monthly, 15 minute long, follow up phone call from the study dietitian. participants will be instructed to complete a 3-day food log before each visit. they will also be asked to record their dairy intake on a daily basis in a dedicated log book. these logs will be collected and analyzed by the study dietitian. dairy consumption will be calculated as the sum of servings per day of milk, cheese, yogurt, and other dairy foods.

Eligibility criteria:
inclusion criteria: 1. subject is participating in the weight achievement and intensive treatment (why wait) program 2. subject is male or female ages 18-75 3. subject has type 2 diabetes for at least three months prior to screening and treated with any antihyperglycemic medication exclusion criteria: 1. subject is pregnant or lactating 2. subject has a heart pacemaker

Keywords: type 2 diabetes obesity nutrition dairy
study of predictive biomarkers for rational management of drug-resistant epilepsy associated with focal cortical dysplasia

Conditions: Refractory Epilepsy; Focal Epilepsy; Focal Cortical Dysplasia

Summary: focal cortical dysplasias (fcds) are neurodevelopmental disorders that represent a major cause of early onset drug-resistant epilepsies with cognitive and behavioral impairments, carrying a lifelong perspective of disability and reduced quality of life. despite a major medical and socio-economic burden, rationale therapeutic strategies are still under debate. surgical removal of the epileptogenic brain area (epileptogenic zone) is the most successful treatment, yet it fails to control fcd-associated seizures in as much as 40% of cases. precise definition and complete resection of the epileptogenic zone are the main determinants of outcome. in current practice of french centers, up to 80% fcd-patients require an intracranial eeg (iceeg) recording to accurately define the epileptogenic zone. however, the indications for iceeg in mri-visible fcd remain empirical and are essentially based on expert opinion.


Eligibility criteria:
inclusion criteria: * adult or pediatric patient suffering from drug-resistant focal epilepsy; * age more than 2 years old; * brain mri suggestive of fcd or normal; * standardized presurgical evaluation available including medical history, scalp video-eeg, 3t mri, fdg-pet, neuropsychological tests; * inpatient in one of the participating centers for recording seizure during long term scalp video-eeg and / or seeg-monitoring; * resective surgery with a minimal post-operative follow-up of 12 months; * histopathologic evidence for fcd or non-pathologic findings (normal histology or mmcd type ii). * patient, parents or legally representative who have given written informed consent to allow the study data collection procedures. exclusion criteria: * brain mri suggestive of another type of lesion; * difficulty to read or understand french, or inability to understand the information; * pregnant or breastfeeding woman; * subject under judicial protection. * other lesion discovered on histological examination; * fcd type 3, dual pathology, ambiguous or unavailable neuropathological findings * lack of longitudinal pre- and post-surgical follow-up.

Keywords: focal cortical dysplasia pronostic epilepsy surgery epiletogenicity index seeg
effectiveness of a nurse-led personalized telephone intervention on lifestyle changes in diabetes prevention.

Conditions: Prediabetic State

Summary: a randomized, 9-months, parallel-group study comparing the effectiveness of a nurse-led telephone personalized lifestyle intervention versus automated smss on nutritional and physical activity advice in the reduction of fasting blood glucose and/or hba1c in a population with prediabetes.

it is estimated that about 70% of the prediabetic population will eventually develop type 2 diabetes (t2dm), contributing to the significant economic burden on health systems and societies. when prediabetes is recognized, lifestyle intervention including weight loss through diet and exercise can reduce the relative risk of developing t2dm by more than 50% within 3 years. in the context of the current pandemic caused by covid-19 the implementation of prevention strategies is heavily affected. telemedicine consultations give patients the opportunity to receive personalized advice on disease prevention even in times of pandemic. previous studies on telemedicine intervention strategies for the prevention of t2dm show that there is a need to further explore the utility of telemedicine and especially telephone-based personalized behavioural interventions in patients with prediabetes.the aim of the present research is to determine whether a nurse-led personalized telephone lifestyle intervention is effective in reducing risk factors associated with the development of t2dm in subjects with prediabetes, versus automated short message service (sms).

Eligibility criteria:
inclusion criteria: * fasting plasma glucose between 100 and 125 mg/dl or hba1c between 5.7 and 6.4% * bmi ≥ 27 and \< 40 kg/m2 * written informed consent exclusion criteria: * documented history of t2dm or use of oral antidiabetic medication * terminal illness * institutionalization, dementia or cognitive impairment * pregnancy * major surgery or hospital stay during the previous 3 months * documented history of hematologic disease which may interfere with the hba1c measurement * presence of any medical or psychological condition that may limit the ability of the patient to participate in the study * concomitant active participation in another clinical trial

Keywords: prediabetes type 2 diabetes fasting plasma glucose diet physical activity randomized clinical trial
the efficacy of the traditional chinese medicine niubang pill combined with methotrexate on active rheumatoid arthritis

Conditions: Niu Bang Zi Pill; Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a chronic, systemic, inflammatory autoimmune disease that results in the destruction of joints, connective tissues, muscle, tendons and fibrous tissue. effective therapy to manage ra still does not exit at present. jia wei niu bang zi pill (nbzp) consists of chinese herbals which has been widely used in the treatment of ra patients in china for hundreds of years to relieve pain and prevent the affected joints pejorative. however, there is no systematic trials to prove the effect of nbzp for management of ra.

a multicenter, randomized, double-blind, placebo-controlled clinical trials will be conducted to determine whether the nbzp could make an effect of pain relief and joints protection. 120 patients suffering from active ra will be enrolled and treated with nbzp or placebo for 3 months. the primary outcome measures are the rate of american college of rheumatology (acr) 50, changes of the disease activity score (das) 28 from the baseline to 3 months and the van der heijde modified sharp score would be measured from the baseline to 12 months. the second outcome measures are the change rate of acr20, acr70, health assessment questionnaire - disability index, change score of patient assessment of arthritis pain, patient global assessment of arthritis, patient global assessment of arthritis and the athens insomnia scale (ais) from the baseline to 2 weeks, 1 month, 2 months, 3 months, 6 months, and 12 months' follow-up.

Eligibility criteria:
inclusion criteria: * adults with rheumatoid arthritis (score more then 5 of acr (american college of rheumatology) /eular (european league against rheumatism), 2009 ) * moderate-to-severe disease activity (disease activity score for 28-joint counts (das28) of more than 3.2 * an onset of symptoms within 12 months before enrollment, no prior exposure to more than 10mg oral glucocorticoids or biologic agents * paid employment or unpaid but measurable work (e.g. caring for a family and home) exclusion criteria: * combined with other disease such as adjuvant arthritis, lupus arthritis, osteoarthritis and et al. * abnormal liver and my kidney function * pregnancy or have a plan of pregnancy,breast feeding women * severe chronic or acute disease interfering with therapy attendance * alcohol or substance abuse

Keywords: traditional chinese medicine niu bang zi pill methotrexate active rheumatoid arthritis
atorvastatin for the reduction of ventricular arrhythmias

Conditions: Arrhythmia

Summary: to assess in patients with cad \[coronary artery disease\] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring icd \[implantable cardioverter defibrillator\] intervention) within one year after randomization.


Eligibility criteria:
inclusion criteria: * eligible subjects were male or female subjects, age \>18 years, with clinically documented coronary artery disease and life-threatening ventricular arrhythmias who met the following criteria: * were scheduled for an icd implantation or had an icd implantation within 1 month, according to the class i american college of cardiology/american heart association (acc/aha) practice guidelines for icd therapy or * were already treated with an icd for a class i acc/aha indication for more than one month, provided they received at least one appropriate icd intervention (shock or antitachycardia pacing (atp) for ventricular tachycardia or ventricular fibrillation) during the preceding six months exclusion criteria: * patients with ventricular arrhythmias in the acute phase of myocardial infarction (first 48 hours). * patients with incessant ventricular tachycardia. * patients with ventricular arrhythmias without underlying coronary artery disease. * patients with a transient or reversible cause of ventricular arrhythmias (including significant electrolyte disturbances or drug induced proarrhythmia).

Keywords: tachycardia, ventricular ventricular fibrillation
hydrocortisone 50 mg every 6 hours compared to hydrocortisone 300 mg per day in treatment of septic shock.

Conditions: Septic Shock

Summary: we performed a multicenter, prospective, randomized, double-blind, pilot study in four adult medical intensive care units. patients presenting septic shock were rapidly administered one of two regimens of hydrocortisone, either a 50-mg intravenous bolus every six hours during seven days (200-mg group) or a 100-mg initial bolus followed by a continuous infusion of 300 mg daily for five days (300-mg group). hydrocortisone was stopped abruptly at the end of treatment.

hydrocortisone hemisuccinate (hydrocortisone upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent. the placebo was saline serum supplied as 10 ml ampoules. the study drugs were administered according to two protocols. in the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. in the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days. in the two groups, hydrocortisone was stopped abruptly at the end of treatment. the investigators had the choice or resuming hydrocortisone at the end of the fifth day if deemed necessary.

Eligibility criteria:
inclusion criteria: * patients over 18 years old * septic shock in accordance with the american college of chest physicians/society of critical care medicine consensus committee criteria. septic shock was managed in accordance with the 2004 edition of the surviving sepsis campaign guidelines. * no minimal vasopressor dose was needed to enter the trial. exclusion criteria: * medical history of adrenal insufficiency * ongoing corticosteroid treatment * pregnancy
safety and efficacy of tadalafil vs. tadalafil with sildosin in the management of moderately and severely symptomatic patients of prostatic hyperplasia

Conditions: Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia

Summary: to study safety and efficacy of tadalafil vs. tadalafil with sildosin in the management of moderately and severely symptomatic patients of prostatic hyperplasia

introduction benign prostatic hyperplasia (bph) is a common cause of lower urinary tract symptoms (luts) in middle-aged and elderly men, and the incidence rate of luts associated with bph (luts/bph) increases with age. luts can be broadly grouped into: (i) storage symptoms, such as frequency, urgency, and nocturia (ii) voiding symptoms, such as intermittency, weak stream and straining, and (iii) post-micturition symptoms, such as a feeling of incomplete emptying and post micturition dribble. for optimal management of luts/bph, medications should be chosen based on age, disease progression, need for long-term management, and other clinical parameters. alpha 1 adreno-receptors antagonists (alpha 1 blockers) are proposed as first-line drug therapy for luts/bph as these agents reduce the adrenergic tone of the smooth muscle within the prostate and bladder neck, thereby relieving the bladder outlet obstruction. tadalafil (phosphodiesterase type 5 \[pde-5\] inhibitor) was approved for treating luts/bph. the inhibition of pde-5leads to accumulation of cyclic guanosine monophosphate in the smooth muscles of the prostate and urethra which causes their relaxation resulting in alleviation of the symptoms of luts/bph.

Eligibility criteria:
inclusion criteria: * patients to be included in the study will be either: 1. diagnosis of bph based on abdominal ultrasound or digital rectal examination. 2. moderate ipss score between 8 : 19. 3. severe ipss score between 20 : 35. 4. post void volume \> 100 c. 5. prostate size 50 to 80 gm. 6. 2 or more weeks of freedom or washout from any medications known to influence luts before enrollment. 7. mental and physical capacity to understand and fill out the study questionnaires. exclusion criteria: 1. contraindications to sildosin or tadalafil. 2. diagnosis of prostate cancer. 3. possible presence of urinary infection, neurogenic bladder, stone bladder, refractory retention, hematuria of prostate origin or any cause for surgical intervention. 4. clinically significant cardiovascular, hepatic, or renal disorders. 5. cataract surgery planned during the study period.
hydroxyurea in treating patients with epstein-barr virus-associated primary cns lymphoma and aids

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of hydroxyurea in treating patients with epstein-barr virus-associated primary cns lymphoma and aids.

objectives: i. estimate the objective response rate of pcnsl in aids patients treated with hydroxyurea. ii. investigate whether levels of epstein-barr virus (ebv) dna in the blood or cerebral spinal fluid are correlates of pcnsl disease activity. outline: this is an open label pilot study. patients receive oral hydroxyurea tid. a course of hydroxyurea consists of 4 weeks of therapy. on day 28, after the first course of treatment, tumor size is analyzed by mri. if no reduction in tumor size is seen on day 28, hydroxyurea dose is increased. if a cr or pr is demonstrated, patients continue on the same treatment at the original dose. mri evaluation is again taken on day 56 of treatment. patients with progressive disease at this evaluation are considered to have no treatment response. projected accrual: 15-25 patients will be enrolled. approximately 8-10 patients will be accrued annually.

Eligibility criteria:
disease characteristics: histologically proven ebv-associated primary cns lymphoma hiv infection confirmed by a positive elisa and western blot patient characteristics: age: open to children and adults of any age performance status: karnofsky at least 50% life expectancy: at least 4 weeks hematopoietic: hemoglobin at least 6.9 gm/dl anc at least 500/mm3 platelet count at least 50,000/mm3 hepatic: bilirubin no greater than 1.5 x upper limit of normal (uln) (1.5 to 2.5 x uln if receiving indinavir) renal: creatinine no greater than 1.5 x uln cardiovascular: not specified other: not pregnant or nursing contraception required in fertile patients prior concurrent therapy: biologic therapy: not specified chemotherapy: not specified endocrine therapy: not specified radiotherapy: not specified surgery: not specified other: prior or concurrent antiretroviral therapy allowed no prior ebv-associated primary cns lymphoma therapy within 1 week of study

Keywords: aids-related primary cns lymphoma